Hormonal
Transoral outlet reduction (TORe) using argon plasma coagulation (APC) induces a significant increase in postprandial peptide YY (PYY) levels, particularly in patients who have undergone cholecystectomy, whereas APC combined with suturing does not produce this effect.
If you have regained weight after gastric bypass due to a stretched connection (anastomosis), endoscopic tightening with argon plasma coagulation (APC) may help restore your body's natural satiety signals, specifically Peptide YY (PYY). This effect is particularly strong if you have had your gallbladder removed. This suggests that choosing the right endoscopic technique (APC vs. suturing) matters for hormonal health and potentially long-term weight management.
The APC cohort presented an increase in PYY levels at 90 minutes, while the APC-suture group did not... cholecystectomized individuals experienced an increase in AUC of PYY between 30 and 120 minutes, while non-cholecystectomized individuals had a non-significant decrease.
Why this rating
The study is a substudy of a randomized trial with a small sample size (n=36) and lacks histological validation for the proposed cell repopulation mechanism.
Source
Endoscopic transoral outlet reduction induces enterohormonal changes in patients with weight regain after Roux-en-Y gastric bypass
Vitor Brunaldi et al. · Endoscopy International Open · 2024
DOI 10.1055/a-2312-5742
More from this paper
- Transoral outlet reduction (TORe) delays the postprandial decrease in ghrelin levels by approximately 30 minutes, shifting the nadir from 30 minutes to 60-90 minutes, without significantly altering the total ghrelin exposure (AUC) or correlating with clinical success.Moderate
- One year after TORe, patients experience a significant overall decrease in postprandial Glucagon-like peptide-1 (GLP-1) levels, regardless of the specific technique used (APC vs. suture) or clinical success status.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →